Ki67 targeted strategies for cancer therapy

• C. Yang ^[1] ; J. Zhang ^[1] ; M. Ding ^[1] ; K. Xu ^[1] ; L. Li ^[1] ; L. Mao ^[1] ; J. Zheng ^[1]
  1. [1] Xuzhou Medical University, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 5 (May 2018), 2018, págs. 570-575
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy.